CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab'
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
This combination aims to offer an effective tool to manage symptoms of nausea and vomiting during pregnancy
The plant is yet to start commercial operations
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
Subscribe To Our Newsletter & Stay Updated